Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The power of similarities to accelerate antiviral development for COVID-19

Posted on January 11th, 2022 by

In April 2020, I wrote a blog post entitled “Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development,” where I described research areas leveraging genetic and phenotypic similarities between SARS-CoV-2 and other known viruses. In my quest to find relevant data, I used Reaxys Medicinal Chemistry to generate a list of substances that interact with enterovirus 3C proteases, a target showing striking similarities with the main proteases of SARS-CoV and SARS-CoV-2. A set of interesting derivatives using a cyanohydrin as an anchor group caught my attention.1 Interestingly, Pfizer used the cyano warhead a few months later to design their protease inhibitor (PF-07321332). Pfizer’s antiviral forms a complex structure with SARS-CoV-2 Mpro, demonstrating the efficacy of the cyano warhead to form a covalent bond with the cysteine residue at the active site.2

(more…)

AI-driven innovation in Life Sciences: Data Science & AI amplifies your innovative drug R&D capabilities

Posted on November 4th, 2021 by

If you work in Life Sciences & Health, you’re likely aware of what Data Science and AI can bring to the table when it comes to sparking innovation. However, if you are not Big Pharma, it’s the how that slows down most LSH companies and organizations. We believe that Elsevier’s road-tested data and semantic technologies can address the challenges of Life Science data.

(more…)

Emerging trends for pancreatitis in the scientific literature: a new report

Posted on October 19th, 2021 by

Elsevier has just released the Emerging trends for pancreatitis in the scientific literature report, which identifies proteins and genes linked to pancreatitis. Elsevier’s Professional Services team prepared it pro bono for Mission: Cure, a foundation that is focused on finding a disease-modifying treatment for pancreatitis. The team hopes that all researchers working on pancreatitis, which affects millions of people worldwide in both acute and chronic forms, will find it useful.

(more…)

Accelerating synthetic chemistry with a predictive retrosynthesis solution

Posted on August 12th, 2021 by

In most aspects of life, we think of “endless possibilities” as a good thing. But in science, the wealth of possibilities can be daunting. Pharmaceutical researchers typically start with a disease that they want to tackle, find a target, and then try to identify compounds which interact with that target. There may be around 200-300 drug candidates per project, and synthesis planning and execution usually takes four to eight weeks per drug candidate. This process requires many chemists and a huge, costly effort to proceed.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. …
  6. 92